1. Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma

   • Colby S. Shemesh
   • Priya Agarwal
   • Dan Lu

   Original Article Open access 28 March 2020 Pages: 831 - 842

   

2. Evaluating the immunoproteasome as a potential therapeutic target in cisplatin-resistant small cell and non-small cell lung cancer

   • Tetsuaki Shoji
   • Eiki Kikuchi
   • Satoshi Konno

   Original Article 30 March 2020 Pages: 843 - 853

   

3. Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors

   • Akihito Kawazoe
   • Yasutoshi Kuboki
   • Takayuki Yoshino

   Original Article Open access 31 March 2020 Pages: 855 - 862

4. Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancer

   • Igal Kushnir
   • Ranjeeta Mallick
   • Neil M. Reaume

   Original Article 02 April 2020 Pages: 863 - 868

5. Assessment of pharmacokinetic variations of capecitabine after multiple administration in rats: a physiologically based pharmacokinetic model

   • Shuhei Sakai
   • Shinji Kobuchi
   • Toshiyuki Sakaeda

   Original Article 02 April 2020 Pages: 869 - 880

   

6. Pharmacokinetics and pharmacogenetics of high-dose methotrexate in Chinese adult patients with non-Hodgkin lymphoma: a population analysis

   • Lin Yang
   • Hui Wu
   • Rui-xiang Xie

   Original Article 03 April 2020 Pages: 881 - 897

   

7. Effects of repeated oral doses of ketoconazole on a sequential ascending single oral dose of fedratinib in healthy subjects

   • Ken Ogasawara
   • Christine Xu
   • Gopal Krishna

   Original Article 04 April 2020 Pages: 899 - 906

   

8. A phase I study investigation of metabolism, and disposition of [¹⁴C]-anlotinib after an oral administration in patients with advanced refractory solid tumors

   • Yiqian Liu
   • Lianke Liu
   • Yongqian Shu

   Original Article Open access 07 April 2020 Pages: 907 - 915

   

9. Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer

   • Sanne C. F. A. Huijberts
   • Robin M. J. M. van Geel
   • Jan H. M. Schellens

   Original Article 09 April 2020 Pages: 917 - 930

   

10. Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: a phase I exposure escalation study

    • L. H. Mammatas
    • A. S. Zandvliet
    • H. M. W. Verheul

    Original Article Open access 09 April 2020 Pages: 931 - 940

    

11. Rapid decrease in serum VEGF-A levels may be a worse prognostic biomarker for patients with platinum-resistant recurrent ovarian cancer treated with bevacizumab and gemcitabine

    • Hiroaki Soyama
    • Morikazu Miyamoto
    • Masashi Takano

    Original Article 11 April 2020 Pages: 941 - 947

    

12. Inhibition of cyclin-dependent kinases by AT7519 enhances nasopharyngeal carcinoma cell response to chemotherapy

    • Xin Wei
    • Jiabin Nian
    • Min Zeng

    Original Article 11 April 2020 Pages: 949 - 957

    

13. Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation

    • Bin Fan
    • David Dai
    • Hua Yang

    Original Article 15 April 2020 Pages: 959 - 968

    

14. The influence of PD-L1 genetic variation on the prognosis of R0 resection colorectal cancer patients received capecitabine-based adjuvant chemotherapy: a long-term follow-up, real-world retrospective study

    • Jinsong Su
    • Baiyun Dai
    • Junmin Song

    Original Article 20 April 2020 Pages: 969 - 978

    

15. Intravenous 5-fluoro-2′-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors

    • Geraldine O.’Sullivan Coyne
    • Lihua Wang
    • James H. Doroshow

    Original Article Open access 20 April 2020 Pages: 979 - 993

    

16. A phase I study of the effect of repeated oral doses of pantoprazole on the pharmacokinetics of a single dose of fedratinib in healthy male subjects

    • Ken Ogasawara
    • Bradley Vince
    • Gopal Krishna

    Original Article 22 April 2020 Pages: 995 - 1001

    

17. Cerebrospinal fluid penetration of the colony-stimulating factor-1 receptor (CSF-1R) inhibitor, pexidartinib

    • Priya S. Shankarappa
    • Cody J. Peer
    • Katherine E. Warren

    Short Communication 18 April 2020 Pages: 1003 - 1007

    

18. Correction to: Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer

    • Hani M. Babiker
    • Mohammed Milhem
    • Thai Ho

    Correction 25 March 2020 Pages: 1009 - 1010